

## Ulcerative Colitis and Crohn's Disease Committee meeting

**Date:** 15/01/2018

**Location:** Manchester

**Minutes:** Final

<b>Committee members present:</b>		
Tessa Lewis (Chair)		(Present for notes 1 – 6)
Charmian Banks		(Present for notes 1 – 6)
Rachel Cooney		(Present for notes 2 – 5)
Sarah Cripps		(Present for notes 1 – 6)
Jenny Epstein		(Present for notes 1 – 6)
Bruce George		(Present for notes 1 – 6)
Richard Harris		(Present for notes 1 – 6)
Sophia Joseph		(Present for notes 1 – 6)
Thomas Mytton		(Present for notes 4 – 6)
Robert Palmer		(Present for notes 1 – 6)
Megan Prydderch		(Present for notes 4 – 6)
Janindra Warusavitarne		(Present for notes 1 – 6)

<b>In attendance:</b>		
<b>Omnia Abdulrazeg</b>	Technical Analyst	(Present for notes 1 – 6)
<b>Chris Carmona</b>	Senior Technical Analyst	(Present for notes 1 – 6)
<b>Susannah Gyton-Moon</b>	Programme Manager	(Present for notes 1 – 6)
<b>James Hall</b>	Content Editor	(Present for notes 4 – 6)
<b>Leslie Hayes</b>	Business Analyst	(Present for notes 1 – 6)
<b>Caroline Keir</b>	Guideline Commissioning Manager	(Present for notes 1 – 5)
<b>Bernadette Li</b>	Technical Analyst – Health Economics	(Present for notes 1 – 6)
<b>Gabriel Rogers</b>	Technical Advisor - Health Economics	(Present for notes 1 – 6)

<b>Apologies:</b>	
Joan Gavin	Committee member
Themba Mudege	Committee member

### **1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the second meeting on Ulcerative Colitis and Crohn's Disease. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: to discuss the preliminary evidence for ulcerative colitis and to define the review protocol for Crohn's disease.

### **Introductions**

The Chair welcomed all to the second meeting. The Crohn's Disease lay members joined the Committee after lunch for the Crohn's Disease review protocol discussion.

### **2. Confirmation of matter under discussion, and declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was the clinical and cost effectiveness of corticosteroids, aminosalicylates, immunomodulators and other relevant drugs vs. placebo, themselves and each other for the induction of remission in ulcerative colitis and to develop a recommended sequence strategy for drug treatment in induction of remission in ulcerative colitis. Also, the efficacy and safety of post-surgical treatment for maintenance of remission of Crohn's disease for 12 months or longer.

The Chair asked everyone to verbally declare any interests.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

### **3. Presentations – Ulcerative Colitis**

The Chair introduced Omnia Abdulrazeg, technical analyst, who presented the interim analysis for the ulcerative colitis review question.

The Chair introduced Bernadette Li, health economist, who discussed with the Committee the details of the economic model.

The Chair thanked all for their presentations.

### **4. Presentations - processes**

After lunch, the Chair welcomed the two Crohn's Disease lay members to the

Committee.

The Chair introduced Caroline Keir, guideline commissioning manager, who gave a presentation about the role of the Commissioning team in guideline development.

The Chair introduced Les Hayes, business analyst, who described how the resource impact team supports the implementation of recommendations made by NICE guideline committees.

The Chair introduced James Hall, content editor, who described how the evidence reviews and recommendations are edited before consultation and publication.

The Committee were given opportunity to ask questions about these processes. The Chair thanked all for their presentations.

**5. Presentations – Crohn’s Disease**

The Chair introduced Megan Prydderch and Thomas Mytton who described their experiences of Crohn’s Disease to the rest of the Committee members.

The Chair reintroduced Omnia Abdulrazeg who discussed the draft review protocol for the Crohn’s disease review question, asking for their input on population, interventions, comparators and outcomes.

**6. Other issues**

There were no items for AOB and the Chair closed the meeting.

**Date of next meeting:** 28/02/2018

**Location of next meeting:** Manchester